EU/3/06/415: Orphan designation for the prevention of rejection for corneal transplant


Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2010 on request of the sponsor.

On 3 November 2006, orphan designation (EU/3/06/415) was granted by the European Commission to Dr Manfred Zoltobrocki, Germany, for ciclosporin (implant) for the prevention of rejection of corneal transplant.

The sponsorship was transferred to Lux Biosciences GmbH, Germany, in December 2006.

Key facts

Active substance
Intended use
Prevention of rejection for corneal transplant
Orphan designation status
EU designation number
Date of designation
Lux Biosciences GmbH
Dreieichstr. 59
D-60594 Frankfurt am Main
Telephone: + 49 69 5050 65 991
Telefax: + 49 69 5050 65 980

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating